JAMAL SALEH: Open Payments
NPI 1306112776 · DETROIT, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,242 in 94 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $395 · 2025 $2,242
Food & beverage: $2,019Education: $223
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 22 | $521 |
| Janssen Pharmaceuticals, Inc | 15 | $334 |
| Teva Pharmaceuticals USA, Inc. | 8 | $324 |
| Otsuka America Pharmaceutical, Inc. | 19 | $299 |
| Luye Pharma (USA) Ltd. | 8 | $169 |
| Alkermes, Inc. | 6 | $147 |
| Neurocrine BioSciences, Inc. | 1 | $124 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $100 |
| Vanda Pharmaceuticals Inc. | 3 | $88 |
| Lundbeck LLC | 4 | $82 |
Products named: COBENFY, INVEGA SUSTENNA, ABILIFY MAINTENA, REXULTI, ERZOFRI EXTENDED-RELEASE, ARISTADA, INGREZZA, UZEDY.
Industry payments across MI — which companies pay providers there.
